Alpha Cognition’s (ACOG) “Buy” Rating Reaffirmed at HC Wainwright

Alpha Cognition (NASDAQ:ACOG)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a report issued on Monday,Benzinga reports. They currently have a $20.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 261.66% from the company’s current price.

Separately, Raymond James upgraded Alpha Cognition to a “moderate buy” rating in a research note on Tuesday, March 25th.

Alpha Cognition Stock Performance

Shares of ACOG opened at $5.53 on Monday. The firm has a market cap of $88.59 million, a PE ratio of -2.16 and a beta of 2.50. Alpha Cognition has a 1 year low of $4.66 and a 1 year high of $7.00. The stock has a 50 day moving average of $5.85.

Institutional Investors Weigh In On Alpha Cognition

Hedge funds and other institutional investors have recently made changes to their positions in the company. National Bank of Canada FI bought a new position in Alpha Cognition in the fourth quarter valued at about $69,000. Manatuck Hill Partners LLC bought a new position in shares of Alpha Cognition in the 4th quarter valued at about $395,000. Tudor Investment Corp ET AL bought a new position in shares of Alpha Cognition in the 4th quarter valued at about $412,000. MYDA Advisors LLC acquired a new stake in shares of Alpha Cognition during the 4th quarter worth approximately $589,000. Finally, Bleichroeder LP bought a new stake in shares of Alpha Cognition during the fourth quarter worth approximately $1,024,000.

About Alpha Cognition

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.